Oman Medical Devices Market Report 2026: MOH Registration, Royal Hospital, and Vision 2040 Commercial Intelligence

The Oman medical devices market is estimated at USD 240–280 million in 2026, growing at approximately 6% CAGR through 2030. MOH Oman procurement accounts for approximately 70% of total device spend, with private hospitals — including Aster Royal, Badr Al Samaa, and Al Hayat International — accounting for the remainder. Oman Vision 2040's healthcare privatization commitments are gradually expanding the private channel and creating new procurement pathways beyond MOH. Because Oman has limited domestic device manufacturing capacity, the large majority of device supply is imported, which makes distributor selection and MOH registration timelines the two factors most likely to determine how quickly a manufacturer can reach the market.

The Ministry of Health Oman (MOH) oversees medical device registration through its Directorate General of Pharmaceutical Affairs, which administers device listing alongside pharmaceutical registration under a shared regulatory structure. Oman accepts CE-marked and FDA-cleared devices with supporting technical documentation, and reference-agency approvals from a recognized regulator can shorten the technical review for many device classes. Registration timelines typically range from 6–18 months. Once registered, devices move into the MOH Central Medical Stores and CSSD (Central Sterile Supply Department) system, which handles hospital-level procurement committees and annual tender cycles. Royal Hospital (the flagship academic medical center) and Sultan Qaboos University Hospital are the two highest-priority accounts, since MOH's centralized tendering process routes the largest device volumes through these facilities before distribution to secondary hospitals. BioNixus tracks MOH Oman registration and procurement cycles by device category.

Diagnostic imaging, cardiovascular devices, diabetes care equipment, and patient monitoring systems are Oman's leading medical device segments by value. Diabetes prevalence (~19% adult population) creates strong structural demand for glucose monitoring and insulin delivery devices. Cardiovascular disease and cancer are the two leading causes of mortality, driving demand for cardiac intervention devices and oncology-related diagnostic and therapeutic equipment. Cardiovascular disease alone accounts for roughly 28% of all-cause mortality in Oman, while national cancer registry data records approximately 3,500 new cancer cases annually, with colorectal and breast cancer the most prevalent — sustaining steady demand for radiotherapy equipment, surgical oncology instruments, and diagnostic imaging platforms at Royal Hospital's National Oncology Centre. Orthopedic implants and trauma equipment form another consistent growth category, driven largely by Khoula Hospital's role as Oman's Level 1 trauma referral center.

Oman Vision 2040's health pillar targets a 35% private sector healthcare share (vs. approximately 30% currently), expansion of health insurance coverage to expatriate residents, and development of integrated health cities. The Oman Health Information System (OHIS) digitalization is improving procurement data visibility. These structural shifts are expected to accelerate private hospital medical device procurement and create more competitive tender dynamics as private insurance coverage grows. The planned integrated health cities are expected to combine public and private capacity under one campus model, and as these facilities come online they should generate incremental demand for advanced diagnostic imaging, patient monitoring, and surgical equipment beyond what existing MOH hospitals currently procure.

Royal Hospital Muscat is Oman's flagship tertiary care center and the country's highest-value medical device account. Royal Hospital operates specialist programs in cardiac surgery, neurology, oncology, and organ transplantation — creating disproportionate demand for high-acuity devices relative to its bed count. Key Account Management strategy in Oman typically prioritizes Royal Hospital and Sultan Qaboos University Hospital before other MOH facilities. Sultan Qaboos University Hospital adds an academic dimension to this dynamic, since its research and training programs often influence which device technologies are adopted first and subsequently referenced by MOH's wider tendering process. Secondary facilities such as Khoula Hospital and Al Nahdha Hospital typically adopt new device categories only after they have been validated at these two lead institutions.

Oman participates in a GCC-wide mutual recognition mechanism that allows medical devices already approved by another Gulf regulator — such as Saudi Arabia's SFDA or the UAE's MOHAP — to be referenced during MOH Oman's technical review. In practice this can shorten the evaluation stage for lower- and moderate-risk device classes, since much of the underlying technical dossier has already been assessed elsewhere in the region. High-risk implantable and life-sustaining devices generally still undergo a full independent MOH Oman review regardless of prior GCC approval. For manufacturers already active elsewhere in the Gulf, a common strategy is to sequence registrations — filing first in a faster-moving GCC market and then referencing that approval in the Oman submission — to compress overall regional launch timelines. BioNixus tracks GCC mutual recognition outcomes across member states to help manufacturers plan multi-country registration sequencing.

Yes — MOH Oman registration and tender participation require a locally licensed distributor or agent registered with Omani authorities, consistent with practice across most GCC markets. The local agent is typically responsible for maintaining registration dossiers, managing after-sales service and technical support obligations, and representing the manufacturer in MOH tender submissions and hospital-level procurement discussions. Given Oman's concentrated public-sector procurement structure, the choice of distributor materially affects a manufacturer's access to Royal Hospital, Sultan Qaboos University Hospital, and other MOH facilities, since incumbent distributors often hold long-standing relationships with hospital procurement committees. Manufacturers entering Oman for the first time typically benefit from selecting a distributor with an existing footprint across both MOH tenders and private hospital groups such as Aster Royal and Badr Al Samaa.

The Oman Health Information System (OHIS) digitalization program is expanding electronic health record coverage and improving procurement data visibility across MOH facilities, gradually shifting demand toward connected diagnostic and monitoring devices that integrate with hospital IT systems. Royal Hospital and Sultan Qaboos University Hospital, as Oman's leading academic and referral centers, are typically the earliest adopters of networked patient monitoring, telehealth-enabled diagnostic equipment, and digital imaging systems. As OHIS matures, MOH's centralized tendering process is increasingly favoring devices with proven interoperability and data-security compliance over standalone equipment. This shift creates an incremental advantage for device manufacturers that can demonstrate integration capability with Oman's national health information infrastructure alongside traditional clinical performance data.

BioNixus delivers longitudinal hospital consumption analogue analytics, payer and formulary committee qualitative boards, bilingual HCP trackers where relevant, tender and access intelligence aligned to MOH registration and hospital procurement at The Royal Hospital and national centres in Oman, KOL mapping, and adoption modelling for healthcare and life sciences. Teams receive decision-ready outputs cross-validated against EphMRA and BHBIA governance with GDPR-aligned multinational fieldwork coordinated from London and regional hubs.